SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment

Overexpression of phosphoprotein phosphatase 2A predicts worse prognosis in patients with breast cancer: a 15-year follow-up

(2017) Po-Ming Chen et al.   HUMAN PATHOLOGY

aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.

(2017) Richard G. Gray et al.   JOURNAL OF CLINICAL ONCOLOGY

Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer

(2016) Eun-Shin Lee et al.   BMC CANCER

Comparison of Breast Cancer Recurrence and Outcome Patterns Between Patients Treated From 1986 to 1992 and From 2004 to 2008

(2015) Rachel J.D. Cossetti et al.   JOURNAL OF CLINICAL ONCOLOGY

SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A

(2015) Man-Hsin Hung et al.   Oncotarget

Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer

(2015) Hao Liu et al.   Oncotarget

PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects

(2015) Raúl Rincón et al.   Oncotarget

Paclitaxel resistance in MCF-7/PTX cells is reversed by paeonol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway

(2015) WEIPENG ZHANG et al.   Molecular Medicine Reports

Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer

(2014) I. Cristobal et al.   CLINICAL CANCER RESEARCH

Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer

(2014) M. Janghorban et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer

(2013) Parthasarathy Seshacharyulu et al.   CANCER LETTERS

Cancerous Inhibitor of Protein Phosphatase 2A, an Emerging Human Oncoprotein and a Potential Cancer Therapy Target

(2013) A. Khanna et al.   CANCER RESEARCH

Patterns of Recurrence and Outcome According to Breast Cancer Subtypes in Lymph Node–Negative Disease: Results From International Breast Cancer Study Group Trials VIII and IX

(2013) Otto Metzger-Filho et al.   JOURNAL OF CLINICAL ONCOLOGY

Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer

(2013) Ivana Sestak et al.   JNCI-Journal of the National Cancer Institute

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Protein phosphatase 2A: a target for anticancer therapy

(2013) Danilo Perrotti et al.   LANCET ONCOLOGY

Hazard of Recurrence among Women after Primary Breast Cancer Treatment--A 10-Year Follow-up Using Data from SEER-Medicare

(2012) L. Cheng et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

(2012) Christina Davies et al.   LANCET

SET protein accumulates in HNSCC and contributes to cell survival: Antioxidant defense, Akt phosphorylation and AVOs acidification

(2012) Andréia M. Leopoldino et al.   ORAL ONCOLOGY

The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM

(2010) Stephen B. Edge et al.   ANNALS OF SURGICAL ONCOLOGY

An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients

(2009) Balazs Györffy et al.   BREAST CANCER RESEARCH AND TREATMENT

Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

(2009) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients

(2009) A K Samanta et al.   ONCOGENE

Multiple pathways regulated by the tumor suppressor PP2A in transformation

(2008) Jukka Westermarck et al.   TRENDS IN MOLECULAR MEDICINE